Non-Medical Switching or Discontinuation Patterns Among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis

Overview

Journal J Mark Access Health Policy

Publisher MDPI

Specialty Public Health

Date 2024 Sep 24

PMID 39315122

Authors

Michael Ingham

Hela Romdhani

Aarti Patel

Veronica Ashton

Gabrielle Caron-Lapointe

Anabelle Tardif-Samson

Patrick Lefebvre

Marie-Helene Lafeuille

Affiliations

Soon will be listed here.

Abstract

This study assessed direct-acting oral anticoagulant (DOAC) switching/discontinuation patterns in patients with non-valvular atrial fibrillation (NVAF) in 2019, by quarter (Q1-Q4), and associated socioeconomic risk factors. Adults with NVAF initiating stable DOAC treatment (July 2018-December 2018) were selected from Symphony Health Solutions' Patient Transactional Datasets (April 2017-January 2021). Switching/discontinuation rates were reported in 2019 Q1-Q4, separately. Non-medical switching/discontinuation (NMSD) was defined as the difference between switching/discontinuation rates in Q1 and mean rates across Q2-Q4. The associations of socioeconomic factors with switching/discontinuation were assessed. Of 46,793 patients (78.7% ≥ 65 years; 52.6% male; 7.7% Black), 18.0% switched/discontinued their initial DOAC in Q1 vs. 8.8% on average in Q2-Q4, corresponding to an NMSD of 9.2%. During the quarter following the switch/discontinuation, more patients who switched/discontinued in Q1 remained untreated (Q1: 77.0%; Q2: 74.3%; Q3: 71.2%) and fewer reinitiated initial DOAC (Q1: 17.6%; Q2: 20.8%; Q3: 24.0%). Factors associated with the risk of switching/discontinuation in Q1 were race, age, gender, insurance type, and household income (all < 0.05). More patients with NVAF switched/discontinued DOACs in Q1 vs. Q2-Q4, and more of them tended to remain untreated relative to those who switched/discontinued later in the year, suggesting a potential long-term impact of NMSD. Findings on factors associated with switching/discontinuation highlight potential socioeconomic discrepancies in treatment continuity.

References

Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J . Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. BMC Cardiovasc Disord. 2019; 19(1):142. PMC: 6567643. DOI: 10.1186/s12872-019-1116-1. View

Kachroo S, Hamilton M, Liu X, Pan X, Brixner D, Marrouche N . Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation. Am J Manag Care. 2016; 22(1):e1-8. View

January C, Samuel Wann L, Calkins H, Chen L, Cigarroa J, Cleveland Jr J . 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the.... J Am Coll Cardiol. 2019; 74(1):104-132. DOI: 10.1016/j.jacc.2019.01.011. View

Farinha J, Jones I, Lip G . Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation. Eur Heart J Suppl. 2022; 24(Suppl A):A42-A55. PMC: 8850710. DOI: 10.1093/eurheartj/suab152. View

Klijn C, Paciaroni M, Berge E, Korompoki E, Korv J, Lal A . Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline. Eur Stroke J. 2020; 4(3):198-223. PMC: 6960695. DOI: 10.1177/2396987319841187. View

Kornej J, Borschel C, Benjamin E, Schnabel R . Epidemiology of Atrial Fibrillation in the 21st Century: Novel Methods and New Insights. Circ Res. 2020; 127(1):4-20. PMC: 7577553. DOI: 10.1161/CIRCRESAHA.120.316340. View

Coleman C, Salam T, Duhig A, Patel A, Cameron A, Voelker J . Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume medicare and medicaid physician providers. J Mark Access Health Policy. 2020; 8(1):1829883. PMC: 7580836. DOI: 10.1080/20016689.2020.1829883. View

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomstrom-Lundqvist C . 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the.... Eur Heart J. 2020; 42(5):373-498. DOI: 10.1093/eurheartj/ehaa612. View

Tsimihodimos V, Gonzalez-Villalpando C, Meigs J, Ferrannini E . Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories. Hypertension. 2018; 71(3):422-428. PMC: 5877818. DOI: 10.1161/HYPERTENSIONAHA.117.10546. View

10.

Eaddy M, Cook C, ODay K, Burch S, Cantrell C . How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012; 37(1):45-55. PMC: 3278192. View

11.

Dhamane A, Hernandez I, Di Fusco M, Gutierrez C, Ferri M, Russ C . Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. Am J Cardiovasc Drugs. 2021; 22(3):333-343. PMC: 9061668. DOI: 10.1007/s40256-021-00501-w. View

12.

Lip G, Banerjee A, Boriani G, Chiang C, Fargo R, Freedman B . Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest. 2018; 154(5):1121-1201. DOI: 10.1016/j.chest.2018.07.040. View

13.

Baum D . Non-medical switching an unmitigated threat to patient care. Am J Prev Cardiol. 2023; 13:100470. PMC: 9947224. DOI: 10.1016/j.ajpc.2023.100470. View

14.

Wharam J, Zhang F, Landon B, Soumerai S, Ross-Degnan D . Low-socioeconomic-status enrollees in high-deductible plans reduced high-severity emergency care. Health Aff (Millwood). 2013; 32(8):1398-406. DOI: 10.1377/hlthaff.2012.1426. View

15.

Essien U, Lusk J, Dusetzina S . Cost-Sharing Reform for Chronic Disease Treatments as a Strategy to Improve Health Care Equity and Value in the US. JAMA Health Forum. 2022; 3(12):e224804. DOI: 10.1001/jamahealthforum.2022.4804. View

16.

Choudhry N, Saya U, Shrank W, Greenberg J, Melia C, Bilodeau A . Cost-related medication underuse: prevalence among hospitalized managed care patients. J Hosp Med. 2011; 7(2):104-9. DOI: 10.1002/jhm.948. View

17.

Baker C, Dhamane A, Mardekian J, Dina O, Russ C, Rosenblatt L . Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Adv Ther. 2018; 36(1):162-174. PMC: 6318235. DOI: 10.1007/s12325-018-0840-8. View

18.

Essien U, Holmes D, Jackson 2nd L, Fonarow G, Mahaffey K, Reiffel J . Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. JAMA Cardiol. 2018; 3(12):1174-1182. PMC: 6583087. DOI: 10.1001/jamacardio.2018.3945. View

19.

Costa O, Salam T, Duhig A, Patel A, Cameron A, Voelker J . Specialist physician perspectives on non-medical switching of prescription medications. J Mark Access Health Policy. 2020; 8(1):1738637. PMC: 7144249. DOI: 10.1080/20016689.2020.1738637. View

20.

Dolinar R, Kohn C, Lavernia F, Nguyen E . The non-medical switching of prescription medications. Postgrad Med. 2019; 131(5):335-341. DOI: 10.1080/00325481.2019.1618195. View